Andrew is a medicinal chemist, neuroscientist, and entrepreneur with interdisciplinary expertise in drug development, with a particular focus on CNS disorders. He is currently engaged in the development of novel opioid receptor modulators for the treatment of mood disorders and physical pain. He serves as the President and Co-Founder of Kures, a startup company aiming to progress these new drug candidates into clinical trials.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
Gilgamesh Pharmaceuticals | Discovery Chemist & Co-Founder | — | — | Detail |